P-123 CLINICAL COURSE OF PATIENTS WITH CHOLESTATIC LIVER DISEASES IN A LIVER TRANSPLANT CENTER

No Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are immune-mediated cholestatic liver diseases, in which inflammation and/or fibrosis result in progressive destrucción of the bile duct. In their clinical course they evolve to cirrhosis and its complications. The objective was to describe the clinical and evolutionary characteristics and long-term survival in patients with cholestatic liver diseases (CLD). Descriptive, longitudinal and ambispective study, in patients with cholestatic liver diseases seen in the hepatology clinic of the Medical Surgical Research Center, between 2000 and 2024, with an average follow-up of 6 years (minimum of 1 and maximum of 14). Patients with PBC or PSC who received treatment with ursodeoxycholic acid and quarterly evaluations were included. The main variables were: initial stage, complications, response to treatment and clinical evolution. The data were processed with the SPSS statistical package version 22.0 on Windows; The analysis was performed by calculating the mean, standard deviation and percentage, and for survival the Kaplan-Meier method was used with a 95% confidence interval. Of 44 patients studied, the most frequent entity was PBC (58.8%). Half of the patients had cirrhosis at the time of diagnosis. Ascites was the most frequent complication (40.9%) and highlighted the insertion of cholangiocarcinoma in 50% of patients with PSC. Most patients had no response to treatment: PBC (61.8%) / PSC (80%). Disease progression was greater in PSC and survival was lower in these patients: 20% at six years. The clinical course of patients with cholestatic liver diseases was determined by the progression of the disease. Patients with PSC had a more torpid evolution, which led to poor survival in long-term follow-up.